Abstract
Background: Lung cancers or (Bronchogenic-Carcinomas) are the disease in certain parts of the lungs in which irresistible multiplication of abnormal cells leads to the inception of a tumor. Lung cancers consisting of two substantial forms based on the microscopic appearance of tumor cells are: Non-Small-Cell-Lung-Cancer (NSCLC) (80 to 85%) and Small-Cell-Lung-Cancer (SCLC) (15 to 20%).
Discussion: Lung cancers are existing luxuriantly across the globe and the most prominent cause of death in advanced countries (USA & UK). There are many causes of lung cancers in which the utmost imperative aspect is the cigarette smoking. During the early stage, there is no perspicuous sign/symptoms but later many symptoms emerge in the infected individual such as insomnia, headache, pain, loss of appetite, fatigue, coughing etc. Lung cancers can be diagnosed in many ways, such as history, physical examination, chest X-rays and biopsy. However, after the diagnosis and confirmation of lung carcinoma, various treatment approaches are existing for curing of cancer in different stages such as surgery, radiation therapy, chemotherapy, and immune therapy. Currently, novel techniques merged that revealed advancements in detection and curing of lung cancer in which mainly includes: microarray analysis, gene expression profiling.
Conclusion: Consequently, the purpose of the current analysis is to specify and epitomize the novel literature pertaining to the development of cancerous cells in different parts of the lung, various preeminent approaches of prevention, efficient diagnostic procedure, and treatments along with novel technologies for inhibition of cancerous cell growth in advance stages.
Keywords: Lung cancer, smoking, tumor, bronchoscopy, biopsy, diagnosis, surgery.
Graphical Abstract
[1]
Landis SH, Murray T, Bolden S, Wingo P. Cancer statistics 1999. CA Cancer J Clin 1999; 49: 8-31.
[http://dx.doi.org/10.3322/canjclin.49.1.8]
[http://dx.doi.org/10.3322/canjclin.49.1.8]
[2]
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-86.
[http://dx.doi.org/10.1002/ijc.29210]
[http://dx.doi.org/10.1002/ijc.29210]
[3]
Berhard J, Ganz PA. Psychosocial issues in lung cancer patients (part 2). Chest 1991; 99: 480-5.
[http://dx.doi.org/10.1378/chest.99.2.480]
[http://dx.doi.org/10.1378/chest.99.2.480]
[4]
Douglas IS, White SR. Should non-small cell carcinoma of the lung be treated with chemotherapy? Con: therapeutic empiricism-the case against chemotherapy in non-small cell lung cancer. Am J Respir Crit Care Med 1995; 151: 1288-91.
[http://dx.doi.org/10.1164/ajrccm.151.5.7735575]
[http://dx.doi.org/10.1164/ajrccm.151.5.7735575]
[5]
Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999; 91: 1194-210.
[http://dx.doi.org/10.1093/jnci/91.14.1194]
[http://dx.doi.org/10.1093/jnci/91.14.1194]
[6]
Williams MD, Sandler AB. The epidemiology of lung cancer. Cancer Treat Res 2001; 105: 31-52.
[http://dx.doi.org/10.1007/978-1-4615-1589-0_2]
[http://dx.doi.org/10.1007/978-1-4615-1589-0_2]
[7]
Mathioudakis A, Hardavella G. From lung cancer screening to targeted therapies: the endless race against lung cancer morbidity and mortality. J Lung Cancer Diagn Treat 2016. 3(S1): 1e101.
[9]
Kumar R, et al. Quantum magnetic resonance therapy: Targeting biophysical cancer vulnerabilities to effectively treat and palliate. J Clin Exp Oncol 2016; 5: 2.
[http://dx.doi.org/10.4172/2324-9110.1000156]
[http://dx.doi.org/10.4172/2324-9110.1000156]
[10]
Parvathi MVS, et al. Micro RNA-142-5p profile as a predictor of tumour markers regulation in different histological grades of human breast carcinoma. J Clin Exp Oncol 2016; 5: 2.
[11]
Slaoui W, et al. Unusual ulcerated nodules of scalp with histological proof of cutaneous metastasis derived from prostate cancer: report of a case. J Clin Exp Oncol 2015; 4: 3.
[12]
Atalay C, et al. Impact of loco-regional under-treatment in elderly patients with early breast cancer (Protocol Yameka-09sdlt); multi-centric retrospective cohort study. J Clin Exp Oncol 2014; 3: 1.
[13]
De Iuliis F, et al. Unexpected vocal cord paralysis and myasthenia gravis in a patient with squamous cell lung cancer. J Clin Exp Oncol 2014; 3: 2.
[14]
Kassim YL, et al. Biomimetic three-dimensional cell culturing: colorectal cancer micro-tissue engineering. J Clin Exp Oncol 2014; 3: 2.
[15]
Maite LD, et al. Atipic axillary mass: Follicular dendritic cell sarcoma within castleman’s disease: a case report and review of literature. J Clin Exp Oncol 2014; 3: 4.
[16]
Brahmbhatt MM, et al. Highly complex chromosomal rearrangements in patients with chronic myeloid leukemia: An Indian experience. J Clin Exp Oncol 2015; 4: 4.
[http://dx.doi.org/10.4172/2324-9110.1000148]
[http://dx.doi.org/10.4172/2324-9110.1000148]
[17]
Khalid A, Javaid MA. Matrix metalloproteinases: new targets in cancer therapy. J Cancer Sci Ther 2016; 8: 143-5.
[http://dx.doi.org/10.4172/1948-5956.1000406]
[http://dx.doi.org/10.4172/1948-5956.1000406]
[18]
Peterson HE, et al. Stereotactic radiosurgery is a safe and effective method of prolonging survival and managing symptoms in patients with brainstem metastases. J Cancer Sci Ther 2015; 7: 192-7.
[http://dx.doi.org/10.4172/1948-5956.1000349]
[http://dx.doi.org/10.4172/1948-5956.1000349]
[19]
Chen GG. Thromboxane is smoking-induced carcinogenesis-potential new pathways for intervention. In: 5th world on cell and stem cell research. 2015 March 23-25; Chicago, Illinois, USA.
[20]
Akcay S, Dedekarginoglu BE. Smoking cessation in lung cancer. J Lung Cancer Diagn Treat 2016; 1: 105.
[21]
Das S, et al. A prospective study to evaluate clinical radia-tion induced pneumonitis in lung cancer patients and its dose response relationship with radiotherapy. J Lung Cancer Diagn Treat 2016; 1: 101.
[22]
Choi H, Mazzone P. Radon and lung cancer: assessing and mitigating the risk. Cleve Clin J Med 2014; 81(9): 567-75.
[http://dx.doi.org/10.3949/ccjm.81a.14046]
[http://dx.doi.org/10.3949/ccjm.81a.14046]
[23]
Muscat JE, Stellman SD, Zhang ZF, et al. Cigarette smoking and large cell carcinoma of the lung. Cancer Epidemiol Biomarkers Prev 1997; 6: 477-80.
[24]
Stewart SL, Cardinez CJ, Richardson LC, et al. Surveillance for cancers associated with tobacco use-United States, 1999-2004. MMWR Surveill Summ 2008; 57: 1-33.
[25]
Alberg AJ, Brock MV, Ford JG, Samet JM, Spivack SD. Epidemiology of lung cancer: diagnosis and management of lung cancer 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143(5 suppl): e1S-e29S.
[http://dx.doi.org/10.1378/chest.12-2345]
[http://dx.doi.org/10.1378/chest.12-2345]
[26]
O’Reilly KM, Mclaughlin AM, Beckett WS, Sime PJ. As-bestos-related lung disease. Am Fam Physician 2007; 75(5): 683-8.
[28]
Alberg AJ, Brock MV, Samet JM. Epidemiology of lung cancer” Murray & Nadel’s Textbook of Respiratory Medicine. 6th ed. Saunders: Elsevier 2016.
[29]
Chen H, Goldberg MS, Villeneuve PJ. A systematic review of the relation between long-term exposure to ambient air pollution and chronic diseases. Rev Environ Health 2008; 23(4): 243-97.
[30]
Yang IA, Holloway JW, Fong KM. Genetic susceptibility to lung cancer and co-morbidities. J Thorac Dis 2013; 5(Suppl. 5): S454-62.
[31]
Sellers T, Yang P. Familial and genetic influences on risk of lung cancer The Genetic Basis of Common Diseases. New York, NY: Oxford University 2002.
[32]
Hwang SJ, Cheng LS, Lozano G, Amos CI, Gu X, Strong LC. Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Hum Genet 2003; 113(3): 238-43.
[http://dx.doi.org/10.1007/s00439-003-0968-7]
[http://dx.doi.org/10.1007/s00439-003-0968-7]
[33]
Vineis P, Husgafvel-Pursiainen K. Air pollution and cancer: biomarker studies in human populations. Carcinogenesis 2005; 26: 1846-55.
[http://dx.doi.org/10.1093/carcin/bgi216]
[http://dx.doi.org/10.1093/carcin/bgi216]
[34]
Pope CA III, Burnett RT, Thun MJ, et al. Lung cancer, car-diopulmonary mortality, and long-term exposure to fine particulate air pollution. JAMA 2002; 287: 1132-41.
[http://dx.doi.org/10.1001/jama.287.9.1132]
[http://dx.doi.org/10.1001/jama.287.9.1132]
[35]
Knop CS. Lung cancer Cancer nursing: Principles and practice. 6th ed. Boston, MA: Jones & Bartlett 2005.
[36]
Van Cleave JH, Cooley ME. Lung cancer A cancer sourcebook for nurses. 8th ed. Sudbury, MA: Jones & Bartlett 2004.
[37]
Gift AG, Jablonski A, Stommel M, Given CW. Symptom clusters in elderly patients with lung cancer. Oncol Nurs Forum 2004; 31(2): 203-.
[http://dx.doi.org/10.1188/04.ONF.203-212]
[http://dx.doi.org/10.1188/04.ONF.203-212]
[38]
Beckles MA, Spiro SG, Colice GL, Rudd RM. Initial evaluation of the patient with lung cancer. Chest 2003; 123(Suppl. 1): 97S-104S.
[http://dx.doi.org/10.1378/chest.123.1_suppl.97S]
[http://dx.doi.org/10.1378/chest.123.1_suppl.97S]
[39]
Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008, Cancer incidence and mortality worldwide: International agency for research on cancer; 2010.Available from: . http://globocan.iarc.fr
[40]
Jemal A, Thun MJ, Ries LAG, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008; 100(23): 1672-94.
[http://dx.doi.org/10.1093/jnci/djn389]
[http://dx.doi.org/10.1093/jnci/djn389]
[41]
Howlader N, Noone AM, Krapcho M, et al. SEER Cancer statistics review, 1975-2009 vintage. 2009; populations). National Cancer Institute, Bethesda, MD 2012.Available from: http://seer.cancer.gov/csr/1975_2009_pops09/
[42]
Caraballoso M, Sacristan M, Serra C, et al. Drugs for preventing lung cancer in healthy people. Cochrane Database Syst Rev 2003; (2): CD002141
[43]
Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc 2008; 83: 355-67.
[http://dx.doi.org/10.4065/83.3.355]
[http://dx.doi.org/10.4065/83.3.355]
[44]
Brambilla E, Pugatch B, Geisinger K, et al. Large cell carcinoma World Health organization classification of tumours pathology and genetics of tumours of the lung, pleura, thymus and heart. Geneva: WHO Press 2004.
[46]
Spiro SG, Gould MK, Colice GL. Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007; 132(3 Suppl): 149S-60S.
[47]
Silvestri GA, Tanoue LT, Margolis ML, Barker J, Detterbeck F. The noninvasive staging of non-small cell lung cancer: the guidelines. Chest 2003; 123: 147S-56S.
[http://dx.doi.org/10.1378/chest.123.1_suppl.147S]
[http://dx.doi.org/10.1378/chest.123.1_suppl.147S]
[48]
Antoch G, et al. Non-small cell lung cancer: dualmodality PET/CT in preoperative staging 1. Radiology 2003; 229: 526-33.
[http://dx.doi.org/10.1148/radiol.2292021598]
[http://dx.doi.org/10.1148/radiol.2292021598]
[49]
Thunnissen FBJM. Sputum examination for early detection of lung cancer. J Clin Pathol 2003; 56: 805-10.
[http://dx.doi.org/10.1136/jcp.56.11.805]
[http://dx.doi.org/10.1136/jcp.56.11.805]
[50]
Hubers AJ, Prinsen CFM, Sozzi G, Witte BI, Thunnis-sen E. Molecular sputum analysis for the diagnosis of lung cancer. Br J Cancer 2013; 109: 530-7.
[http://dx.doi.org/10.1038/bjc.2013.393]
[http://dx.doi.org/10.1038/bjc.2013.393]
[51]
Navani N, Spiro SG, Janes SM. Mediastinal staging of NSCLC with endoscopic and endobronchial ultrasound. Nat Rev Clin Oncol 2009; 6: 278-86.
[http://dx.doi.org/10.1038/nrclinonc.2009.39]
[http://dx.doi.org/10.1038/nrclinonc.2009.39]
[52]
Navani N, et al. Lung cancer diagnosis and staging with endo-bronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label, pragmatic, randomised controlled trial. Lancet Respir Med 2015; 3: 282-9.
[http://dx.doi.org/10.1016/S2213-2600(15)00029-6]
[http://dx.doi.org/10.1016/S2213-2600(15)00029-6]
[53]
Hehn BT, Haponik E, Rubin HR, Lechtzin N, Diette GB. The relationship between age and process of care and patient tolerance of bronchoscopy. J Am Geriatr Soc 2003; 51: 917-22.
[54]
Du Rand IA, Blaikley J, Booton R, et al. British thoracic society guideline for diagnostic flexible bronchoscopy in adults: accredited by NICE. Thorax 2013; 68(Suppl. 1): i1-i44.
[http://dx.doi.org/10.1136/thoraxjnl-2013-203618]
[http://dx.doi.org/10.1136/thoraxjnl-2013-203618]
[55]
Rivera MP, Mehta AC. Initial diagnosis of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132: 131S-48S.
[http://dx.doi.org/10.1378/chest.07-1357]
[http://dx.doi.org/10.1378/chest.07-1357]
[56]
Schreiber G, McCrory DC. Performance characteristics of different modalities for diagnosis of suspected lung cancer: summary of published evidence. Chest 2003; 123: 115S-28S.
[http://dx.doi.org/10.1378/chest.123.1_suppl.115S]
[http://dx.doi.org/10.1378/chest.123.1_suppl.115S]
[57]
Varela-Lema L, Fernández-Villar A, Ruano-Ravina A. Effectiveness and safety of endobronchial ultrasound-transbronchial needle aspiration: a systematic review. Eur Respir J 2009; 33: 1156-64.
[http://dx.doi.org/10.1183/09031936.00097908]
[http://dx.doi.org/10.1183/09031936.00097908]
[58]
Kurimoto N. End-bronchial ultrasonography using a guide sheath increases the ability to diagnose peripheral pulmonary lesions endoscopically. Chest 2004; 126: 959-65.
[http://dx.doi.org/10.1378/chest.126.3.959]
[http://dx.doi.org/10.1378/chest.126.3.959]
[59]
Catalano MF, Rosenblatt ML, Chak A, et al. Endoscopic ultrasound-guided fine needle aspiration in the diagnosis of mediastinal masses of unknown origin. Am J Gastroenterol 2002; 97: 2559-65.
[http://dx.doi.org/10.1111/j.1572-0241.2002.06023.x]
[http://dx.doi.org/10.1111/j.1572-0241.2002.06023.x]
[60]
Detterbeck FC, Jantz MA, Wallace M, Vansteenkiste J, Silvestri GA. Invasive mediastinal staging of lung cancer.ACCP evidencebased clinical practice guidelines (2nd edition). Chest 2007; 132: 202S-S.
[http://dx.doi.org/10.1378/chest.07-1362]
[http://dx.doi.org/10.1378/chest.07-1362]
[61]
Toba H, Kondo K, Otsuka H, et al. Diagnosis of the presence of lymph node metastasis and decision of operative indication using fluorodeoxyglucose-positron emission tomography and computed tomography in patients with primary lung cancer. J Med Invest 2010; 57: 305-13.
[http://dx.doi.org/10.2152/jmi.57.305]
[http://dx.doi.org/10.2152/jmi.57.305]
[62]
Silvestri GA, Hoffman BJ, Bhutani MS, et al. Endoscopic ultrasound with fine-needle aspiration in the diagnosis and staging of lung cancer. Ann Thorac Surg 1996; 61: 1441-5.
[http://dx.doi.org/10.1016/0003-4975(95)00052-6]
[http://dx.doi.org/10.1016/0003-4975(95)00052-6]
[63]
Fritscher-Ravens A. Endoscopic ultrasound evaluation in the diagnosis and staging of lung cancer. Lung Cancer 2003; 41: 259-67.
[64]
Hernandez A, Kahaleh M, Olazagasti J, et al. EUS-FNA as the initial diagnostic modality in centrally located primary lung cancers. J Clin Gastroenterol 2007; 41: 657-60.
[http://dx.doi.org/10.1097/MCG.0b013e31802fc1cf]
[http://dx.doi.org/10.1097/MCG.0b013e31802fc1cf]
[65]
Singh S, Thakur M. Diagnosis of recurrent lung cancer in the mediastinum using endosonographically guided fine-needle aspiration biopsy. J Clin Ultrasound 2009; 37: 230-2.
[http://dx.doi.org/10.1002/jcu.20539]
[http://dx.doi.org/10.1002/jcu.20539]
[66]
Lai R. Endoscopic ultrasound-guided fine needle aspiration for diagnosis of recurrent non-small cell lung cancer. Ann Thorac Surg 2005; 80: 2346-9.
[http://dx.doi.org/10.1016/j.athoracsur.2004.06.060]
[http://dx.doi.org/10.1016/j.athoracsur.2004.06.060]
[67]
Kim H, Chung SJ, Kim SG, et al. Endoscopic ultrasonographyphy-guided fine needle aspiration for computed tomography-negative and positron emission tomography-positive mediastinal lymph node in a patient with recurrent lung cancer. Gut Liver 2007; 1: 90-2.
[http://dx.doi.org/10.5009/gnl.2007.1.1.90]
[http://dx.doi.org/10.5009/gnl.2007.1.1.90]
[68]
Varadarajulu S, Schmulewitz N, Wildi SM, et al. Accuracy of EUS in staging of T4 lung cancer. Gastrointest Endosc 2004; 59: 345-8.
[http://dx.doi.org/10.1016/S0016-5107(03)02541-0]
[http://dx.doi.org/10.1016/S0016-5107(03)02541-0]
[69]
Annema JT, Veersteegh MI, Veselic M, et al. Endoscopic ultrasound added to mediastinos-copy for preoperative staging of patients with lung cancer. JAMA 2005; 294: 931-6.
[http://dx.doi.org/10.1001/jama.294.8.931]
[http://dx.doi.org/10.1001/jama.294.8.931]
[70]
Detterbeck FC, Lewis SZ, Diekemper R, Addrizzo-Harris D, Alberts WM. Executive summary: diagnosis and management of lung cancer 3rd ed: American College of Chest Physicians evidencebased clinical practice guidelines. Chest. 2013; 143(5 Suppl): 7S-37S.
[71]
Kinsey CM, Arenberg DA. Endobronchial ultrasound-guided transbronchial needle aspiration for non-small cell lung cancer staging. Am J Respir Crit Care Med 2014; 189: 640-9.
[http://dx.doi.org/10.1164/rccm.201311-2007CI]
[http://dx.doi.org/10.1164/rccm.201311-2007CI]
[72]
Gridelli C, Rossi A, Carbone DP, et al. Non-small-cell lung cancer. Nat Rev Dis Primers 2015; 1: 15009.
[73]
Ferrel B, Koczywas M, Grannis F, et al. Palliative care in lung cancer. Surg Clin North Am 2011; 91(2): 403-17.
[http://dx.doi.org/10.1016/j.suc.2010.12.003]
[http://dx.doi.org/10.1016/j.suc.2010.12.003]
[74]
Hom L, Lovly CM, Johnson DH. Chapter 107. Neoplasm of lung. In: Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J, Ed Harrison’s principles of internal medicine. 9th ed. New York; McGraw- Hill. 2015.
[75]
Manser RL, Irving LB, Stone C, et al. Screening for lung cancer Cochrane library. Chichester, UK: Wiley 2004.
[76]
Fuentes R, Bonfill X, Expósito J. Surgery versus radiosurgery for patients with a solitary brain metastasis from non-small cell lung cancer. Cochrane Libr 2004.
[http://dx.doi.org/10.1002/14651858.CD004840]
[http://dx.doi.org/10.1002/14651858.CD004840]
[77]
Amini A, Yeh N, Gaspar LE, et al. Stereotactic Body Radiation Therapy (SBRT) for lung cancer patients previously treated with conventional radiotherapy: a review. Radiat Oncol 2014; 9: 210.
[http://dx.doi.org/10.1186/1748-717X-9-210]
[http://dx.doi.org/10.1186/1748-717X-9-210]
[78]
Arriagada R, Goldstraw P, Le Chevalier T. Oxford text-book of oncology. 2nd ed. UK: Oxford University Press 2002.
[79]
Hatton MQ, Martin JE. Continuous hyperfractionated accelerated radiotherapy (CHART) and non-conventionally fractionated radiotherapy in the treatment of non-small cell lung cancer: a review and consideration of future directions. Clin Oncol (R Coll Radiol) 2010; 22(5): 356-64.
[http://dx.doi.org/10.1016/j.clon.2010.03.010]
[http://dx.doi.org/10.1016/j.clon.2010.03.010]
[80]
Le Péchoux C. Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data. Oncologist 2011; 16(5): 672-81.
[http://dx.doi.org/10.1634/theoncologist.2010-0150]
[http://dx.doi.org/10.1634/theoncologist.2010-0150]
[81]
Reveiz L, Rueda JR, Cardona AF. Palliative endobronchial brachytherapy for non-small cell lung cancer. Cochrane Database Syst Rev 2012; 12CD004284
[http://dx.doi.org/10.1002/14651858.CD004284.pub3]
[http://dx.doi.org/10.1002/14651858.CD004284.pub3]
[82]
Pfister DG, Johnson DH, Azzoli CG, et al. American society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline: updated 2003. J Clin Oncol 2004; 22(2): 330-53.
[http://dx.doi.org/10.1200/JCO.2004.09.053]
[http://dx.doi.org/10.1200/JCO.2004.09.053]
[83]
Topalian SL, et al. Safety, Activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-54.
[http://dx.doi.org/10.1056/NEJMoa1200690]
[http://dx.doi.org/10.1056/NEJMoa1200690]
[84]
Brahmer JR, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-65.
[http://dx.doi.org/10.1056/NEJMoa1200694]
[http://dx.doi.org/10.1056/NEJMoa1200694]
[85]
Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 path-ways. Immunol Rev 2008; 224: 166-82.
[http://dx.doi.org/10.1111/j.1600-065X.2008.00662.x]
[http://dx.doi.org/10.1111/j.1600-065X.2008.00662.x]
[86]
Lynch TJ, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage iiib/iv non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012; 30: 2046-54.
[http://dx.doi.org/10.1200/JCO.2011.38.4032]
[http://dx.doi.org/10.1200/JCO.2011.38.4032]
[87]
Herbst RS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 563-7.
[http://dx.doi.org/10.1038/nature14011]
[http://dx.doi.org/10.1038/nature14011]
[88]
Casaluce F, et al. Emerging drugs targeting PD-1 and PD-L1: reality or hope? Expert Opin Emerg Drugs 2014; 19: 557-69.
[http://dx.doi.org/10.1517/14728214.2014.964682]
[http://dx.doi.org/10.1517/14728214.2014.964682]
[89]
Lindeman NI, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013; 8: 823-59.
[http://dx.doi.org/10.1097/JTO.0b013e318290868f]
[http://dx.doi.org/10.1097/JTO.0b013e318290868f]
[90]
Mok T, Yang JJ, Lam KC. Treating patients with EGFR-sensitizing mutations: first line or second line-is there a difference? J Clin Oncol 2013; 31: 1081-8.
[http://dx.doi.org/10.1200/JCO.2012.43.0652]
[http://dx.doi.org/10.1200/JCO.2012.43.0652]
[91]
Park K, et al. Aspiration: first-line erlotinib (E) until and beyond RECIST progression (PD) in Asian patients (pts) with EGFR mutation-positive (mut+) NSCLC. Ann Oncol 2014; 25(Suppl. 4): 1223O.
[http://dx.doi.org/10.1093/annonc/mdu349.2]
[http://dx.doi.org/10.1093/annonc/mdu349.2]
[92]
Agra Y, Pelayo M, Sacristan M, et al. Chemotherapy versus best supportive care for extensive small cell lung cancer. Chichester, UK: Willey 2003.
[93]
Pijls-Johannesma MC, De Ruysscher D, et al. Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database of Systematic Reviews 2004.
[http://dx.doi.org/10.1002/14651858.CD004700.pub2]
[http://dx.doi.org/10.1002/14651858.CD004700.pub2]
[94]
Turrisi AT, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340: 265-71.
[http://dx.doi.org/10.1056/NEJM199901283400403]
[http://dx.doi.org/10.1056/NEJM199901283400403]
[95]
Deng G, Cassileth BR, Yeung KS. Complementary therapies for cancer-related symptoms. J Support Oncol 2004; 2: 419-29.
[96]
Wu MT, Hsieh JC, Xiong J, et al. Central nervous pathway for acupuncture stimulation: localization of processing with functional MR imaging of the brain–preliminary experience. Radiology 1999; 212: 133-41.
[http://dx.doi.org/10.1148/radiology.212.1.r99jl04133]
[http://dx.doi.org/10.1148/radiology.212.1.r99jl04133]
[97]
Han JS. Acupuncture: neuropeptide release produced by electrical stimulation of different frequencies. Trends Neurosci 2003; 26: 17-22.
[http://dx.doi.org/10.1016/S0166-2236(02)00006-1]
[http://dx.doi.org/10.1016/S0166-2236(02)00006-1]
[98]
Bedi M, Kharofa J, Zambrano EV, et al. Tumour increase on MRI after neoadjuvant treatment is associated with greater pathologic necrosis and poor survival in patients with soft tissue sarcoma. J Interv Oncol 2013; 2(2): 109.
[99]
Ahmed OM. Relationships between oxidative stress, cancer development and therapeutic interventions. Cancer Med Anticancer Drug 2016; 1(2): 1e104.
[100]
Elbasateeny SS, Ibrahim TR, Hegazy AA, Shaheen NE. Diagnostic Discrimination of fine needle aspiration specimens of hepatic nodules using immuno-histochemical expression of GPC3 and EZH2. J Tumor Res 2016; 2: 110.
[101]
Albushra Y. Challenges and questions in the management of metastatic castration resistant prostate cancer. Cancer Med Anticancer Drug 2016; 1: 104.
[102]
Kandesar P, Chikode P, Sabale S. Perspective of Magnetic Fluid Hyperthermia (MFH) for the treatment of tumor. Tumor Res 2016; 2: 111.
[http://dx.doi.org/10.35248/2684-1258.16.2.111]
[http://dx.doi.org/10.35248/2684-1258.16.2.111]
[103]
Francisco JL, Maribel D, Saul S, Esteban G, Carmen L. Multifocal angiosarcoma of the scalp: review of the literature and report of two cases. J Tumor Diag Rep 2015; 1: 103.
[http://dx.doi.org/10.35248/2684-1258.15.1.103]
[http://dx.doi.org/10.35248/2684-1258.15.1.103]
Article Metrics
36
2
1
1